
=> d 13 L3 HAS NO ANSWERS



VPA 13-9/10/11 U NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES: RSPEC 11 3

NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

=> s 13 ful

FULL SEARCH INITIATED 18:05:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 38450 TO ITERATE

100.0% PROCESSED 38450 ITERATIONS

52 ANSWERS

SEARCH TIME: 00.00.03

L4 52 SEA SSS FUL L3

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 167.82 168.03

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 18:05:22 ON 06 FEB 2006 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Feb 2006 VOL 144 ISS 7 FILE LAST UPDATED: 5 Feb 2006 (20060205/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

```
2 L2
L5
=> s 14
             3 L4
L6
=> s 16 not 15
             1 L6 NOT L5
L7
=> d bib abs 1-3 16
     ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
L6
AN
     2005:638858 CAPLUS
DN
     143:153365
TI
     Preparation of heteroaryl ureas and their use as glucokinase activators
     Murray, Anthony; Lau, Jesper; Jeppesen, Lone; Vedso, Per; Ankersen,
IN
     Michael; Lundbeck, Jane Marie; Kristiansen, Marit; Valcarce-Lopez, Maria
     Carmen; Polisetti, Dharma Rao; Subramanian, Govindan; Andrews, Robert
     Carl; Christen, Daniel P.; Cooper, Jeremy T.; Santhosh, Kalpathy
     Chidambareswaran
PA
     Novo Nordisk A/S, Den.
SO
     PCT Int. Appl., 335 pp.
     CODEN: PIXXD2
     Patent
DT
LΑ
     English
FAN.CNT 1
     PATENT NO.
                         KIND
                                DATE
                                            APPLICATION NO.
                                                                    DATE
                                            ------
                         ----
                                20050721
                                            WO 2005-DK2
                                                                    20050106
     WO 2005066145
                          A1
PΙ
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
PRAI DK 2004-13
                                20040106
                          Α
     DK 2004-1272
                                20040823
                          Α
     DK 2004-1897
                                20041207
                          Α
     MARPAT 143:153365
os
GI
```

Η

II

Ι

be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial (no data).

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:756712 CAPLUS

DN 141:260563

TI Preparation of isoquinolinyl piperidinyl/pyrrolidinyl urea derivatives as vanilloid receptor 1 antagonists for the treatment of pain

IN Moss, Stephen Frederick; Rami, Harshad Kantilal; Thompson, Mervyn; Witty, David Richard

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.				KIND DATE				APPLICATION NO.				DATE					
							-											
PI	WO 2004078749				A1		20040916		WO 2004-GB978						20040305			
	1	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
			CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
			GΕ,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KΕ,	KG,	KP,	KR,	KZ,	LC,
			LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI
	;	RW:	BW,	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	ŞL,	SZ,	TZ,	UG,	ZM,	ZW,	AT,	BE,
			BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	IT,	LU,
			MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,
			GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG							
	EP 1603899				A1 20051214			EP 2004-717691					20040305					
		R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
			ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	HU,	PL,	SK
PRAI	GB 2	003-	-516	5		Α		2003	0306									
	GB 2003-16554				A 20030715													
	WO 2	004-	-GB9'	78		W		2004	0305									
OS GI	MARP	AT 1	L41:2	2605	63													

$$\begin{array}{c|c}
P & & & \\
N & & & \\
H & & & \\
H & & \\
\end{array}$$

$$\begin{array}{c|c}
D & & \\
D & & \\
D & & \\
\end{array}$$

$$\begin{array}{c|c}
P & & \\
D & & \\
\end{array}$$

$$\begin{array}{c|c}
P & & \\
D & & \\
\end{array}$$

$$\begin{array}{c|c}
P & & \\
\end{array}$$

AB N-Isoquinolinyl ureas of formula I, wherein P is (un)substituted isoquinolinyl; P' is (un)substituted Ph, pyridinyl, pyrimidinyl or thiazolyl; A is (CH2)r; B is (CH2)s; r is 1-3; s is 0-2; r + s is 2-4; n is 0-3, were prepared as vanilloid receptor 1 antagonists. Compds. I, pharmaceutically acceptable salts and solvates thereof, processes for

II

their preparation, pharmaceutical compns. comprising them, and their use in the treatment or prophylaxis of disorders, such as pain, in which antagonism of the vanilloid receptor 1 (VR1) is beneficial, are claimed. A number of isoquinolinyl piperidinyl/pyrrolidinyl urea derivs. have been synthesized. Thus, condensation of Ph chloroformate with 5-amino-1-methylisoquinoline followed by the addition of 1-(3-chloro-5-(trifluoromethyl)-2-pyridinyl)-4piperidinamine (preparation given), gave urea II, which was then converted into its hydrochloride salt. All synthesized title compds. showed VR1 antagonist activity with pKb > 6 in a FLIPR based calcium assay, and those with pKb > 7 including II·HCl, were tested for FCA-induced hyperalgesia in the guinea pig and found active.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
L6
     2003:97300 CAPLUS
AN
DN
     138:153440
TI
     Preparation of substituted ureas as neuropeptide Y Y5 receptor antagonists
     Stamford, Andrew W.; Huang, Ying; Li, Guoqing
IN
PA
     Schering Corporation, USA
     PCT Int. Appl., 119 pp.
SO
     CODEN: PIXXD2
DT
     Patent
LA
     English
FAN.CNT 1
     PATENT NO.
                        KIND
                               DATE
                                           APPLICATION NO.
                                                                  DATE
                        ____
                                           ______
                               _____
PΙ
     WO 2003009845
                         A1
                               20030206
                                           WO 2002-US23552
                                                                  20020724
     WO 2003009845
                         C2
                               20040311
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU,
             ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD,
            MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK,
             SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
```

CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG 20030206

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

20031106

20031223

20040519

20041229

20050106

20050930

20040527

20010726

20020724

20020724

AA

A1

B2

A1

Α

T2

Α

A1

P

A3

W

CA 2454830

US 6667319

EP 1418913

CN 1558764

NZ 530429

PRAI US 2001-308433P

os GI JP 2005500338

US 2004102474

US 2002-202239

WO 2002-US23552

MARPAT 138:153440

US 2003207860

CA 2002-2454830

US 2002-202239

EP 2002-752562

CN 2002-818964

JP 2003-515237

NZ 2002-530429

US 2003-692559

AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

20020724

20020724

20020724

20020724

20020724

20020724


20031024

AB Substituted ureas [I; wherein X = N, C; Z = (substituted) amino, alkyl; D = H, OH, (substituted) alkyl; E = H, (substituted) alkyl, or D and E together can be independently joined together via an alkylene bridge; Q = H, (substituted) alkyl, or D, X, Q and the carbon to which Q is attached can jointly form a 3 to 7-membered ring; g, j, k, m, n, independently = 0, 1, 2, 3; R1 = 1 to 5 substituents, each independently selected from H, OH, halo, haloalkyl, alkyl, cycloalkyl, CN, etc.; R2, R4, independently = 1 to 6 substituents, each independently selected from H, alkyl, alkoxy, OH, etc.; R3 = H, (substituted) alkyl] were prepared For example, compound (II) was prepared by the claimed methodol. The prepared compds. are potent NPY Y5 receptor antagonists (preferred compds. have range of Ki = 0.2 - 10 nM) and, thus, are useful in the treatment of obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

ΙI

Ι

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT



VAR G1=11/10/8
VAR G2=1/2/3
ENTER (DIS), GRA, NOD, BON OR ?:end
L4 STRUCTURE CREATED

=> 's 14

SAMPLE SEARCH INITIATED 17:48:17 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2415 TO ITERATE

82.8% PROCESSED 2000 ITERATIONS INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED) SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 45353 TO 51247 PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> s 14 ful FULL SEARCH INITIATED 17:48:31 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 47817 TO ITERATE

100.0% PROCESSED 47817 ITERATIONS SEARCH TIME: 00.00.01

L6 78 SEA SSS FUL L4

=> s 16 not 12 L7 75 L6 NOT L2 78 ANSWERS

0 ANSWERS

=> analyze 13
ENTER ANSWER NUMBER OR RANGE (1-):1
ENTER DISPLAY CODE (TI) OR ?:rn
L10 ANALYZE L3 1 RN : 208 TERMS

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 15.28 186.67

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 17:50:11 ON 06 FEB 2006 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 FEB 2006 HIGHEST RN 873536-40-4
DICTIONARY FILE UPDATES: 5 FEB 2006 HIGHEST RN 873536-40-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s 110

L11 208 L10

=> d his

L3

L4

(FILE 'HOME' ENTERED AT 17:44:50 ON 06 FEB 2006)

FILE 'REGISTRY' ENTERED AT 17:44:57 ON 06 FEB 2006

L1 STRUC

L2 3 S L1

FILE 'CAPLUS' ENTERED AT 17:47:04 ON 06 FEB 2006 1 S L2

FILE 'REGISTRY' ENTERED AT 17:47:15 ON 06 FEB 2006 STRUC ' L5 0 S L4 L6 78 S L4 FUL L7 75 S L6 NOT L2

FILE 'CAPLUS' ENTERED AT 17:48:58 ON 06 FEB 2006

L8 39 S L7

L9 38 S L8 NOT L3

L10 ANALYZE L3 1 RN : 208 TERMS


FILE 'REGISTRY' ENTERED AT 17:50:11 ON 06 FEB 2006

L11 208 S L10

=> s 17 not 111

L12 30 L7 NOT L11

=> d l1 L1 HAS NO ANSWERS L1 STR



NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 3 8
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE

```
ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
L3
    2003:97300 CAPLUS
AN
DN
    138:153440
    Preparation of substituted ureas as neuropeptide Y Y5 receptor antagonists
TI
    Stamford, Andrew W.; Huang, Ying; Li, Guoqing
IN
PA
    Schering Corporation, USA
SO
     PCT Int. Appl., 119 pp.
    CODEN: PIXXD2
DT
     Patent
LA
    English
FAN.CNT 1
     PATENT NO.
                        KIND
                               DATE
                                           APPLICATION NO.
                                                                 DATE
                                          -----
     ______
                        ----
                                                                 _____
                                           WO 2002-US23552
    WO 2003009845
                         A1
                               20030206
                                                                  20020724
    WO 2003009845
                        C2
                               20040311
            AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU,
            ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD,
            MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK,
            SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
            CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                               20030206
                                         CA 2002-2454830
     CA 2454830
                         AA
                                                                  20020724
                               20031106
                                           US 2002-202239
                                                                  20020724
    US 2003207860
                         A1
    US 6667319
                         B2
                               20031223
                         A1
                               20040519
                                         EP 2002-752562
    EP 1418913
                                                                  20020724
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
                                         CN 2002-818964
                         Α
                               20041229
                                                                  20020724
                                           JP 2003-515237
     JP 2005500338
                         T2
                               20050106
                                                                  20020724
    NZ 530429
                               20050930
                                           NZ 2002-530429
                                                                  20020724
                         Α
                         A1
                                           US 2003-692559
    US 2004102474
                               20040527
                                                                  20031024
PRAI US 2001-308433P
                         Ρ
                               20010726
                         A3
     US 2002-202239
                               20020724
     WO 2002-US23552
                         W
                               20020724
     MARPAT 138:153440
os
             THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
             ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

	(FILE	'HOME' ENTERED AT 17:44:50 ON 06 FEB 2006)
	FILE	'REGISTRY' ENTERED AT 17:44:57 ON 06 FEB 2006
L1		STRUC
L2		3 S L1
	FTI.E	'CAPLUS' ENTERED AT 17:47:04 ON 06 FEB 2006
L3	LIDD	1 S L2
	FILE	'REGISTRY' ENTERED AT 17:47:15 ON 06 FEB 2006
L4 L5		STRUC 0 S L4
Г2		78 S L4 FUL
ьо ьо		75 S L6 NOT L2
ц,		75 5 DO NOT D2
	FILE	'CAPLUS' ENTERED AT 17:48:58 ON 06 FEB 2006
L8	•	39 S L7
L9		38 S L8 NOT L3
L10		ANALYZE L3 1 RN : 208 TERMS
	FILE	'REGISTRY' ENTERED AT 17:50:11 ON 06 FEB 2006
L11		208 S L10
L12		30 S L7 NOT L11
L13		24 SEARCH L1 SSS SUB=L12 FUL
L14		10 S L13 AND PHENYLMETHYL
L15		14 S L13 NOT L14
	ett.e	'CAPLUS' ENTERED AT 17:54:59 ON 06 FEB 2006
L16	LIDE	30 S L15
L17		O S L16 AND (EAT? OR OBES?)
L18		0 S L16 AND (ANOREX? OR CACH? OR BULLI?)
	FILE	'REGISTRY' ENTERED AT 17:57:37 ON 06 FEB 2006
	FILE	'CAPLUS' ENTERED AT 17:58:19 ON 06 FEB 2006
L19		6 S L14

FILE 'STNGUIDE' ENTERED AT 17:59:22 ON 06 FEB 2006

```
' > s l14
```

L19 6 L14

=> d bib hitstr 1-6

L19 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:777922 CAPLUS

DN 137:279193

TI Preparation of imidazolylalkyl-aminopiperidines as HIV inhbitors

IN Edlin, Christopher David; Redshaw, Sally; Smith, Ian Edward David; Walter, Daryl Simon

PA F. Hoffmann-La Roche A.-G., Switz.

SO PCT Int. Appl., 179 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

11111	PATENT NO.				KIN	D	DATE		APPLICATION NO.						DATE			
PI		WO 2002079186 WO 2002079186							WO 2002-EP3193					20020321				
	WO									-	- D-D	D.C.	-	D11	D.F.	G 3	CII	CDT
		W:							AZ,									
			•	•	•	•	•	•	DM,	•	•	•	-		•	•	•	•
				•		-	-		IS,	-		-		•	-	-	•	-
			LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	PH,	PL,
			PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ΤJ,	TM,	TR,	TT,	TZ,	UA,	ŪĠ,
			UΖ,	VN,	ΥU,	ZA,	zw											
		RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	ŪĠ,	ZM,	ZW,	AM,	ΑZ,	BY,
			KG,	ΚZ,	MD,	RU,	TJ,	TM,	AT,	BE,	CH,	CY,	DE,	DK,	ES,	FI,	FR,	GB,
			GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,
			GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG							
	CA	2441							1010			002-	2441	778		2	0020	321
	BR	2002	0085	72		Α											0020	
	EΡ	1417	202			A2		2004	0512		EP 2	002-	7325	12		2	0020	321
									FR,									
			•	-		-		-	MK,	-	-		,	,				•
	CN	1500	-	,				-	0526				8078	03		2	0020	321
		2004		18					0916		-						0020	
	US 2003069276 ZA 2003006890				A					US 2002-104117 ZA 2003-6890								
TAGG	I GB 2001-8099						2001			un z					2	0000	, , ,	
LKAI		2001						2001										
OC						W		2002	U321									
os	IATET	RPAT	13/:	2/91	73	_		_	_					_		_	_	

IT 46665-61-2P, 1-Benzyl-3-(1-formylpiperidin-4-yl)-1-[1-[[5-methyl-2-(4-trifluoromethylphenyl)-1H-imidazol-4-yl]methyl]piperidin-4-yl]urea RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(HIV inhibitor; preparation of imidazolylalkyl-aminopiperidines as HIV inhbitors)

RN 466665-61-2 CAPLUS

CN Urea, N'-(1-formyl-4-piperidinyl)-N-[1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]-4-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

```
L19 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN
    1999:261205 CAPLUS
DN
    130:267220
    Practical synthesis of ureas
TI
IN
    Thavonekham, Bounkham
    Boehringer Ingelheim (Canada) Ltd., Can.
PA
SO
    Can. Pat. Appl., 39 pp.
    CODEN: CPXXEB
DT
    Patent
    English
LA
FAN.CNT 1
    PATENT NO.
                        KIND
                               DATE
                                          APPLICATION NO.
                                                                 DATE
     _____
                        ----
                               -----
                                           -----
                                                                  _ _ _ _ _ _ _
PΙ
    CA 2215585
                         AA
                               19980317
                                          CA 1997-2215585
                                                                 19970916
    CA 2215585
                         C
                               20040420
                                          US 1997-931006
                                                                 19970915
    US 5925762
                         Α
                               19990720
PRAI US 1996-26202P
                         Ρ
                               19960917
    CASREACT 130:267220; MARPAT 130:267220
OS
IT
    175023-49-1P
    RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP
     (Preparation)
        (practical synthesis of ureas)
RN
    175023-49-1 CAPLUS
CN
    Urea, N,N'-bis[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)
Ph-CH2
                                 . CH2-Ph
               NH-C-NH-
    ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
L19
     1998:259658 CAPLUS
AN
DN
     128:294701
     Preparation of N-bipiperidinylbenzamides and analogs as cell adhesion
ΤI
     inhibitors
     Pieper, Helmut; Linz, Guenter; Austel, Volkhard; Himmelsbach, Frank; Guth,
IN
    Brian; Weisenberger, Johannes
    Dr. Karl Thomae G.m.b.H., Germany
PA
    Ger. Offen., 40 pp.
SO
    CODEN: GWXXBX
DT
    Patent
LA
    German
FAN.CNT 1
                        KIND
                                          APPLICATION NO.
     PATENT NO.
                               DATE
                                                                 DATE
                                          ------
                        ----
                               -----
                                                                 -----
                                         DE 1996-19643331
                                                                 19961021
PΤ
    DE 19643331
                         A1
                               19980423
                                         WO 1997-EP5683
                         A1
                               19980430
                                                                 19971015
     WO 9817646
        W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
            DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR,
            KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,
            PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,
            US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
            GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
            GN, ML, MR, NE, SN, TD, TG
                               19980515
                                          AU 1997-48674
     AU 9748674
                                                                19971015
                        A1
PRAI DE 1996-19643331
                         Α
                               19961021
     WO 1997-EP5683
                         W
                               19971015
os
    MARPAT 128:294701
```

IT 206273-08-7P 206273-33-8P 206273-53-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-bipiperidinylbenzamides and analogs as cell adhesion inhibitors)

RN 206273-08-7 CAPLUS

CN [1,4'-Bipiperidine]-1'-carboxylic acid, 4-[[[1-(2-methoxy-2-oxoethyl)-4piperidinyl]amino]carbonyl](phenylmethyl)amino]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)

RN 206273-33-8 CAPLUS

CN 1-Piperidineacetic acid, 4-[[[[1,4'-bipiperidin]-4-yl(phenylmethyl)amino]carbonyl]amino]-, methyl ester, trihydrochloride (9CI) (CA INDEX NAME)

•3 HCl

RN 206273-53-2 CAPLUS

CN 1-Piperidineacetic acid, 4-[[[[1,4'-bipiperidin]-4-yl(phenylmethyl)amino]carbonyl]amino]-, trihydrochloride (9CI) (CA INDEX NAME)

●3 HCl

IT 206274-07-9P 206274-08-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-bipiperidinylbenzamides and analogs as cell adhesion inhibitors)

RN 206274-07-9 CAPLUS

CN 1-Piperidineacetic acid, 4-[[[[1-[(1,1-dimethylethoxy)carbonyl]-4-piperidinyl](phenylmethyl)amino]carbonyl]amino]-, methyl ester (9CI) (CA

RN 206274-08-0 CAPLUS

CN 1-Piperidineacetic acid, 4-[[[(phenylmethyl)-4-piperidinylamino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{HN} & \text{CH}_2\text{-Ph} \\ \hline & \text{N-C-NH} \\ \hline & \text{O} \\ \end{array}$$
 CH₂-C-OMe

L19 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1997:702201 CAPLUS

DN 128:34510

TI A practical synthesis of ureas from phenyl carbamates

AU Thavonekham, Bounkham

CS Bio-Mega Research Division, Boehringer Ingelheim Ltd., Laval, QC, H7S 2G5, Can.

SO Synthesis (1997), (10), 1189-1194 CODEN: SYNTBF; ISSN: 0039-7881

PB Thieme

DT Journal

LA English

OS CASREACT 128:34510

IT 175023-49-1P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of ureas from Ph carbamates)

RN 175023-49-1 CAPLUS

CN Urea, N,N'-bis[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:476785 CAPLUS

DN . 125:142463

TI Carbodiimide derivatives for use in biotinylations

IN Takenishi, Soichiro; Suzuki, Osamu; Yokomizo, Hirohiko; Ichihara, Tatsuo;

Masuda, Gen; Shiohata, Namiko; Komiya, Kazuko

PA Nisshinbo Industries, Inc., Japan

SO Eur. Pat. Appl., 55 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	O212 2						
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE		
ΡI	EP 718300	A1	19960626	EP 1995-309433	19951222		
	EP 718300	B1	20011121				
	R: DE, FR, GB						
	JP 08176159	A2	19960709	JP 1994-335492	19941222		
	JP 3583489	B2	20041104				
	US 5700935	Α	19971223	US 1995-577374	19951222		
	US 5789588	Α	19980804	US 1997-931714	19970916		
PRAI	JP 1994-335492	Α	19941222				
	US 1995-577374	A3	19951222				

OS MARPAT 125:142463

IT 179542-50-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of carbodiimide derivs. of biotin for use in biotinylations)

RN 179542-50-8 CAPLUS

CN Urea, N-(1-methyl-4-piperidinyl)-N'-[1-(phenylmethyl)-4-piperidinyl]-(9CI) (CA INDEX NAME)

L19 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:95731 CAPLUS

DN 124:260782

TI Synthesis of symmetrical and unsymmetrical ureas using unsymmetrical diaryl carbonates

AU Freer, Richard; McKillop, Alexander

CS Synthetic Chem. Dep., SmithKline Beecham Pharmaceuticals, Harlow, CM19 5AW, UK

SO Synthetic Communications (1996), 26(2), 331-49 CODEN: SYNCAV; ISSN: 0039-7911

PB Dekker

DT Journal

LA English

OS CASREACT 124:260782

IT 175023-49-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 175023-49-1 CAPLUS

CN Urea, N,N'-bis[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)